• No results found

Non-adherence to Anti-TNF Therapy is Associated with Illness Perceptions and Clinical Outcomes in Outpatients with Inflammatory Bowel Disease: Results from a Prospective Multicentre Study (vol 10, pg 549, 2016)

N/A
N/A
Protected

Academic year: 2021

Share "Non-adherence to Anti-TNF Therapy is Associated with Illness Perceptions and Clinical Outcomes in Outpatients with Inflammatory Bowel Disease: Results from a Prospective Multicentre Study (vol 10, pg 549, 2016)"

Copied!
1
0
0

Bezig met laden.... (Bekijk nu de volledige tekst)

Hele tekst

(1)

Copyright © 2018 European Crohn’s and Colitis Organisation (ECCO). Published by Oxford University Press. All rights reserved.

For permissions, please email: journals.permissions@oup.com 1381

Journal of Crohn’s and Colitis, 2018, 1381

doi:10.1093/ecco-jcc/jjy083 Advance Access publication June 30, 2018 Corrigendum

Corrigendum: Non-adherence to Anti-TNF

Therapy is Associated with Illness Perceptions

and Clinical Outcomes in Outpatients with

Inflammatory Bowel Disease: Results from a

Prospective Multicentre Study

Mike van der Have,

a

*

Bas Oldenburg,

a

Ad A. Kaptein,

b

Jeroen M. Jansen,

c

Robert C. H. Scheffer,

d

Bas A. van Tuyl,

e

Andrea E. van der Meulen-de Jong,

f

Marieke Pierik,

g

Peter D. Siersema,

a

Martijn G. H. van Oijen,

a,h

Herma H. Fidder

a

aDepartment of Gastroenterology and Hepatology, University Medical Centre Utrecht, Utrecht, The Netherlands bSection Medical Psychology, Leiden University Medical Centre, Leiden, The Netherlands cDepartment of

Gastroenterology and Hepatology, Onze Lieve Vrouwe Gasthuis, Amsterdam, The Netherlands dDepartment of

Gastroenterology and Hepatology, Jeroen Bosch Hospital, ‘s Hertogenbosch, The Netherlands eDepartment of

Gastroenterology and Hepatology, Diakonessenhuis, Utrecht, The Netherlands fDepartment of Gastroenterology

and Hepatology, Leiden University Medical Centre, Leiden, The Netherlands gDepartment of Gastroenterology

and Hepatology, Maastricht University Medical Centre, Maastricht, The Netherlands hDepartment of Medical

Oncology, Academic Medical Centre, University of Amsterdam, Amsterdam, The Netherlands

*Corresponding author: Mike van der Have, Department of Gastroenterology and Hepatology, University Medical Centre Utrecht, Heidelberglaan 100, PO Box 85500, 3500 GA Utrecht, The Netherlands. Tel.: 00 31 08875 74164; fax: 00 31 08875 55533; email: M.vanderhave@umcutrecht.nl.

doi:10.1093/ecco-jcc/jjw002 Head1=Head2=Head1=Head2/Head1

This article has been updated to take account of the following cor-rection initiated and authorised by the authors. The authors apolo-gize for these errors.

1) The following copyright statement:

“Use of the ©MMAS is protected by US copyright laws. Permission for use is required. A  license agreement is available from: MMAS Research 14725 Bellevue WA” has been added to Table 1, Figure 1, Figure 2 and Supplementary Table 1.

2) Reference 28 was cited incorrectly and has been replaced by the following MMAS-8 references:

Morisky DE, Ang A, Krousel-Wood M, Ward HJ. Predictive validity of a medication adherence measure in an outpatient setting. J Clin Hypertens 2008;10:348–54.

Morisky DE, DiMatteo MR. Improving the measurement of self-reported medication nonadherence: response to authors. J Clin Epidemiol 2011;64:255–7.

3) Reference 30 was cited incorrectly and has been replaced by the following reference:

Krousel-Wood M, Islam T, Webber LS, Re RN, Morisky DE, Muntner P. New medication adherence scale versus pharmacy fill rates in sen-iors with hypertension. Am J Manag Care 2009;15:59–66.

4) The numbered references have been corrected in the reference list and in the article itself.

Referenties

GERELATEERDE DOCUMENTEN

The aim of this study is to assess the number of UC patients who are persistently intolerant to 5-ASA after single-blind rechallenge, to describe the symptoms appearing and to

After discontinuation of 5-ASA the hepatitis resolved Due to the laboratory and histologic results, the diagnosis 5-ASA induced auto-immune hepatitis/small duct PSC overlap

In this study we describe in detail, for the first time, a cohort of patients with inflammatory bowel disease (IBD) who developed nephrotoxicity subsequent to 5-ASA administration.

These false positive samples were six clinical samples with high ATI levels and five quality control samples which only contained serum from healthy controls that was spiked

Different concentrations of IFX, IFX biosimilar CT-P13 (Inflectra), ADA, Certolizumab, Etanercept and Golimumab (0-5-10-20-40-100 ng/mL) were analyzed for their neutralizing

Primary objective of the study is to investigate the efficacy oral IFX biosimilar CT- P13 in ColoPulse tablets to induce clinical remission based on CDAI score of < 150 at week

A novel formulation of CT-P13 (infliximab biosimilar) for subcutaneous administration: 1-year result from a phase 1 open-label randomised controlled trial in patients with

Increasing Infliximab Dose Based on Symptoms, Biomarkers, and Serum Drug Concentrations Does Not Increase Clinical, Endoscopic, and Corticosteroid-Free Remission in Patients With